The crown jewel in Merck’s $11.5B Acceleron buyout just cleared a pivotal PhIII

Amber Tong

Merck consistently spotlighted the multibillion-dollar sales potential of sotatercept, the lead drug in Acceleron’s pipeline, as it explained to investors why it wagered …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

The crown jewel in Merck’s $11.5B Acceleron buyout just cleared a pivotal PhIII

Amber Tong

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Post-Hoc: Pharma CEOs' alternative reality with Trump

FDA lifts hold on Entrada's Duchenne drug after two years

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

How AI can address ongoing challenges in the life sciences industry

The crown jew­el in Mer­ck’s $11.5B Ac­celeron buy­out just cleared a piv­otal PhI­II

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

The crown jewel in Merck’s $11.5B Acceleron buyout just cleared a pivotal PhIII